Article thumbnail

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial

By Hans-Dirk Düngen, Svetlana Apostolović, Simone Inkrot, Elvis Tahirović, Agnieszka Töpper, Felix Mehrhof, Christiane Prettin, Biljana Putniković, Aleksandar N. Nešković, Mirjana Krotin, Dejan Sakač, Mitja Lainščak, Frank Edelmann, Rolf Wachter, Thomas Rau, Thomas Eschenhagen, Wolfram Doehner, Stefan D. Anker, Finn Waagstein, Christoph Herrmann-Lingen, Goetz Gelbrich and Rainer Dietz
Topics: Treatment
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Beta-blockade in heart failure: selective versus nonselective agents.
  2. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of effects of Nebivolol Intervention on outcomes and rehospitalization in seniors with heart failure).
  3. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial.
  4. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or metoprolol European trial (COMET): randomised controlled trial.
  5. (1996). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation
  6. CIBIS-ELD Investigators. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.
  7. (2003). COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet
  8. Dahlstro ¨m U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
  9. Different effects of propranolol, bisoprolol, carvedilol and doxazosin on heart rate, blood pressure, and plasma concentrations of epinephrine and norepinephrine.
  10. (2009). Evaluation of the management of heart failure in primary care. Fam Pract
  11. (2009). focused update incorporated into the ACC/ AHA
  12. (2005). Focused update incorporated into the ACC/AHA
  13. (1999). Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet
  14. Heart failure: epidemiology, aetiology, and prognosis of heart failure.
  15. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.
  16. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
  17. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euroheart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment.
  18. (2008). Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure
  19. (2005). Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and
  20. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet
  21. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET.
  22. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial.
  23. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study.